Shao Lee Lin

Shao-Lee Lin, MD, PhD has extensive experience in the biopharmaceutical industry. From 2001 to 2004, they were a Clinical Scholar and Associate Physician at The Rockefeller University. Shao-Lee then worked at Amgen, Inc. from 2004 to 2012 as an Executive Medical Director of Global Development. From 2012 to 2015, they were Vice President of Inflammation and Respiratory Therapeutics at Gilead Sciences, and from 2015 to 2018 they were a Corporate Officer, Leading Therapeutic Areas, Development Excellence, and International Development, and Vice President of Global Immunology and Renal Development at AbbVie. In 2018, they became Executive Vice President, Head of Research and Development, and Chief Scientific Officer at Horizon. In 2019, they were an Independent Board Director at Principia Biopharma, Board Trustee at Lake Forest College, and Board Director at Third Harmonic Bio. In 2020, they became Chief Executive Officer and co-founder of ACELYRIN, INC. and an Independent Board Director at Surrozen.

Shao-Lee Lin, MD, PhD has a long history of education. Shao-Lee completed their MD/PhD in Immunology from The Johns Hopkins University School of Medicine between 1990 and 1995. Prior to that, they attended Rice University from 1984 to 1988, where they studied Chemical Engineering and Biochemistry.